Skip to content

The study of the characteristics of wide-area retinal refractive distribution in populations with different refractive states.

The study of the characteristics of wide-area retinal refractive distribution in populations with different refractive states.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113212
Enrollment
Unknown
Registered
2025-11-26
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperopia

Interventions

Sponsors

Aier Eye Hospital Group Co., Ltd. Changsha Aier Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1.Age between 6 and 35 years; 2.Spherical equivalent refractive error (manifest refraction) of both eyes ranging from +3.00 D to –7.00 D; 3.Best-corrected visual acuity (BCVA) >= 0.8; 4.Normal anterior segment examination in both eyes, with clear corneas and normal pupillary light reflexes; 5.Able to cooperate with and complete the ophthalmic examination procedures.

Exclusion criteria

Exclusion criteria: 1.Patients with ocular diseases that may affect refractive measurements or constitute a contraindication to mydriasis, including but not limited to glaucoma, iridocyclitis, active ocular inflammation, severe corneal pathology, cataract, lens dislocation, and any significant retinal or optic nerve disease (such as retinal detachment, optic atrophy, etc.); 2.Patients with a history of intraocular surgery (e.g., cataract, glaucoma, or vitreoretinal surgery) or corneal refractive surgery; 3.Patients currently (e.g., within the past month) using medications that may affect ocular accommodation, pupil size, or vascular status, such as atropine or pirenzepine eye drops, systemic anticholinergic drugs, sympathomimetic agents, etc.; 4.Patients with a known allergy to any component of the mydriatic agents used in the study; 5.Patients with severe systemic diseases (such as uncontrolled hypertension, serious cardiovascular disease, hyperthyroidism, epilepsy, asthma, etc.) that make it unsafe to perform mydriasis or to cooperate with the examinations.

Design outcomes

Primary

MeasureTime frame
Axial length;Cycloplegic refraction;Wide-field retinal refraction ;Choroidal Blood Flow;Choroidal thickness;

Countries

China

Contacts

Public ContactZhikuan Yang

Changsha Aier Eye Hospital, Aier Eye Hospital Group Co., Ltd.

yangzhikuan@aierchina.com+86 133 8007 1988

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026